Summary C-reactive protein (CRP) levels in serum were measured in fifteen patients with metastatic colorectal carcinoma, prior to and during treatment with a continuous intravenous infusion of rIL.2. Patients were subsequently classified as responders or non-responders to this therapy. Baseline serum CRP levels, prior to treatment, were significantly lower in the responders (range <2-8 mg-1) when compared with the non-responders (range 7.5-116 mg 1'), P = 0.004. Furthermore, the responding patients demonstrated significantly and grossly elevated CRP stimulation indices (SI) compared with non-responders at different time intervals during the rIL2 infusion. At the cessation of rIL2 therapy, the CRP stimulation index was 31.3 ± 9.3 in the responders, and only 1.6 ± 0.3 in the non-responders (means ± s.e.m, P = 0.014). These Interest has focused on the function of the acute phase proteins in inflammation and malignancy. Of the latter proteins, C-reactive protein (CRP) has been identified as a sensitive, specific and rapidly responsive protein in serum (Weinstein et al., 1984) . CRP has been shown to be induced by various malignancies, including different types of adenocarcinomas, and its level in serum to be elevated in patients with metastatic disease (Weinstein et al., 1984) . We present preliminary data showing that CRP levels in serum may also be used as predictors of response to treatment with rIL2.
Summary C-reactive protein (CRP) levels in serum were measured in fifteen patients with metastatic colorectal carcinoma, prior to and during treatment with a continuous intravenous infusion of rIL.2. Patients were subsequently classified as responders or non-responders to this therapy. Baseline serum CRP levels, prior to treatment, were significantly lower in the responders (range <2-8 mg-1) when compared with the non-responders (range 7.5-116 mg 1'), P = 0.004. Furthermore, the responding patients demonstrated significantly and grossly elevated CRP stimulation indices (SI) compared with non-responders at different time intervals during the rIL2 infusion. At the cessation of rIL2 therapy, the CRP stimulation index was 31.3 ± 9.3 in the responders, and only 1.6 ± 0.3 in the non-responders (means ± s.e.m, P = 0.014). These (West et al., 1987; Rosenberg et al., 1989) . It is, therefore, not surprising that attempts have been made to predict, at an early stage of therapy, which patients will subsequently respond to rIL2 therapy, but to date, it has not been possible to clearly identify these patients.
Interest has focused on the function of the acute phase proteins in inflammation and malignancy. Of the latter proteins, C-reactive protein (CRP) has been identified as a sensitive, specific and rapidly responsive protein in serum (Weinstein et al., 1984) . CRP has been shown to be induced by various malignancies, including different types of adenocarcinomas, and its level in serum to be elevated in patients with metastatic disease (Weinstein et al., 1984) . We present preliminary data showing that CRP levels in serum may also be used as predictors of response to treatment with rIL2.
Materials and methods
Fifteen patients with metastatic colorectal cancer were treated with rIL2 (18 x 106 IU m2 body surface area/24 h), by continuous intravenous infusion for a total of 120 h, combined with three pulses of 5-fluorouracil (600 mg/M2 body surface area), and folinic acid, (25 mg/M2 body surface area), also given intravenously at weekly intervals, starting 48 h after completing the rIL2 infusion. Prior to commencing any treatment, the concentrations of CRP were measured in the patients serum by rate nephelometry (Stemnberg, 1977) , using a Beckman ICS Analyser II with Beckman reagents, calibrators and controls (CRP standardised against WHO CRP standard). The coefficient of variation for CRP measurements is 4% in our laboratory and the lower limit of the assay was 2 mg 1-. In addition, the serum concentrations of CRP during therapy were measured at 12 h, 24 h, 48 h, 72 h and 120 h after the commencement of the rIL2 infusions. levels during the rIL2 infusion were similar to the other non-responders.
Discussion
The acute phase protein, CRP, is one of thirty or more proteins produced by the liver in response to tissue damage and inflammation associated with infections, chronic disease states and malignant disease (Weinstein et al., 1984; Kushner, 1982) . Although different roles, such as inflammatory mediators, scavengers and enzyme inhibitors, have been ascribed to some of these proteins, the precise function of CRP remains to be elucidated. Nevertheless, it is a sensitive and relatively specific marker for monitoring inflammatory condi- (Dinarello, 1984; Baumann et al., 1987; Marinkovic et al., 1989) .
Our data show that a response (partial or complete) to rIL2 occurred only in those patients whose serum CRP was less than 10 mg 1'. In contrast, patients who failed to respond (stasis or progression of disease) to rIL2 therapy had CRP values which were grossly elevated, with the exception of one patient who had baseline levels. The reasons for the substantial pre-treatment difference between responding and non-responding patients remain unclear. All patients in this study had metastatic adenocarcinoma and three of the six responding patients had comparable tumour loads to those of the non-responding group of patients. However, the high baseline levels of CRP may be a reflection of either tumour burden or biological aggressiveness and hence enhanced tumour cell turnover (no patient had evidence of concurrent infection). The elevated levels of CRP induced by rIL2 in the responders may be a measure of cytokine release, in particular TNF, and subsequent beneficial anti-cancer response. Indeed, Blay et al. (1990) showed a correlation between sustained production of TNF and clinical response to rIL2. It is also important to note that the non-responding patient who had low baseline CRP levels (which can occur in patients with extensive tumour deposits) conformed to the pattern shown by all other non-responders, i.e. in failing to demonstrate a CRP response during the rIL2 infusion.
Thus, in assessing patients as to their suitability for continuous intravenous rIL2 therapy, with its associated morbidity and expense, it is apparent that patients who are already demonstrating a significant acute phase response, as demonstrated by increased circulating concentrations of CRP, are unlikely to respond to this treatment. Whilst patients with low baseline levels of CRP, in conjunction with the ability to mount a substantially enhanced CRP response during rIL2 infusion, should be selected for active and possibly prolonged treatment. Further careful studies are needed to confirm these findings and to elucidate the possible underlying mechanisms of anti-cancer activity.
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